SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    JSH Guidelines for the Management of Hepatitis B Virus Infection, Hepatology Research, 2014, 44,
  2. 2
    A. Ayres, L. Yuen, K. M. Jackson, S. Manoharan, A. Glass, M. Maley, W. Yoo, S. P. Hong, S.-O. Kim, F. Luciani, D. S. Bowden, J. Bayliss, M. T. Levy, S. A. Locarnini, Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations, Journal of Viral Hepatitis, 2014, 21, 11
  3. 3
    Paula E. Florian, Alina Macovei, Catalin Lazar, Adina L. Milac, Izabela Sokolowska, Costel C. Darie, Robert W. Evans, Anca Roseanu, Norica Branza-Nichita, Characterization of the anti-HBV activity of HLP1–23, a human lactoferrin-derived peptide, Journal of Medical Virology, 2013, 85, 5
  4. 4
    In Situ Molecular Pathology and Co-expression Analyses, 2013,

    CrossRef

  5. 5
    Robert P. Perrillo, Hie-Won Hann, Eugene Schiff, David Mutimer, Bernard Willems, Nancy Leung, William M. Lee, Susan Dixon, Mary Woessner, Carol L. Brosgart, Lynn D. Condreay, Stephen D. Gardner, Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance, Hepatology International, 2011, 5, 2, 654

    CrossRef

  6. 6
    Osamu Yokosuka, Masayuki Kurosaki, Fumio Imazeki, Yasuji Arase, Yasuhito Tanaka, Kazuaki Chayama, Eiji Tanaka, Hiromitsu Kumada, Namiki Izumi, Masashi Mizokami, Masatoshi Kudo, Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009, Hepatology Research, 2011, 41, 1
  7. 7
    Andrea Snow-Lampart, Brandi Chappell, Maria Curtis, Yuao Zhu, Florence Myrick, James Schawalder, Kathryn Kitrinos, Evguenia S. Svarovskaia, Michael D. Miller, Jeff Sorbel, Jenny Heathcote, Patrick Marcellin, Katyna Borroto-Esoda, No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus, Hepatology, 2011, 53, 3
  8. 8
    Masashi Mizokami, Eiji Tanaka, Kazuaki Chayama, Yasuhito Tanaka, Masayuki Kurosaki, Namiki Izumi, Yasuji Arase, Hiromitsu Kumada, Fumio Imazeki, Osamu Yokosuka, Masatoshi Kudo, JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B, Kanzo, 2010, 51, 5, 243

    CrossRef

  9. 9
    María L. Cuestas, Cintia W. Rivero, María L. Minassian, Amalia I. Castillo, Emiliano A. Gentile, Julieta Trinks, Liliana León, Graciela Daleoso, Bernardo Frider, Carol Lezama, Marcela Galoppo, Gisela Giacove, Verónica L. Mathet, José R. Oubiña, Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina, Antiviral Research, 2010, 87, 1, 74

    CrossRef

  10. 10
    E. Seremba, P. Ocama, C.K. Opio, M. Kagimu, H.J. Yuan, N. Attar, D.L. Thomas, W.M. Lee, Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda, Journal of Medical Virology, 2010, 82, 8
  11. 11
    Ju Hyun Shim, Dong Jin Suh, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone, Hepatology, 2009, 50, 4
  12. 12
    Christian Markus Lange, Bernd Kronenberger, Stefan Zeuzem, Hepatitis B: Management of suboptimal response to oral antiviral therapy, Current Hepatitis Reports, 2009, 8, 4, 173

    CrossRef

  13. 13
    Songtao Li, Haibo Zhou, Guirong Huang, Ning Liu, Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin, Medical Microbiology and Immunology, 2009, 198, 1, 19

    CrossRef

  14. 14
    Antigoni Katsoulidou, Dimitrios Paraskevis, Emmanouil Magiorkinis, Zissis Moschidis, Catherine Haida, Eleni Hatzitheodorou, Agoritsa Varaklioti, Anastasia Karafoulidou, Maria Hatzitaki, Lilian Kavallierou, Athanasia Mouzaki, Evaggelia Andrioti, Chrysanthi Veneti, Athanasia Kaperoni, Eleftheria Zervou, Constantina Politis, Angelos Hatzakis, Molecular characterization of occult hepatitis B cases in Greek blood donors, Journal of Medical Virology, 2009, 81, 5
  15. 15
    Samad Amini-Bavil-Olyaee, Ulf Herbers, Seyed Reza Mohebbi, Farzaneh Sabahi, Mohammad Reza Zali, Tom Luedde, Christian Trautwein, Frank Tacke, Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome, Journal of Hepatology, 2009, 51, 4, 647

    CrossRef

  16. 16
    Samad Amini-Bavil-Olyaee, Ulf Herbers, Julie Sheldon, Tom Luedde, Christian Trautwein, Frank Tacke, The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen–positive and hepatitis B e antigen–negative hepatitis B virus strains, Hepatology, 2009, 49, 4
  17. 17
    Richard A. Heipertz, Jason L. Starkey, Thomas G. Miller, Jianming Hu, Harriet C. Isom, trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase, Virology, 2009, 388, 1, 57

    CrossRef

  18. 18
    Anil Seetharam, Mauricio Lisker-Melman, Treatment of chronic hepatitis B: Are we ready for combination therapy?, Current Gastroenterology Reports, 2009, 11, 1, 22

    CrossRef

  19. 19
    Bo Feng, Lai Wei, Ming Chen, Liping Wang, Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B, Microbiological Research, 2008, 163, 4, 487

    CrossRef

  20. 20
    Reiichiro Kuwahara, Ryukichi Kumashiro, Tatsuya Ide, Yuriko Koga, Teruko Hino, Akiko Hisamochi, Kazuo Tanaka, Kei Ogata, Hiroyuki Koga, Yukari Takao, Michio Sata, Predictive Factors Associated with the Progression to Hepatic Failure Caused by Lamivudine-Resistant HBV, Digestive Diseases and Sciences, 2008, 53, 11, 2999

    CrossRef

  21. 21
    Rui Hua, Yasuo Tanaka, Kenichi Fukai, Motohisa Tada, Motoko Seto, Yoshinari Asaoka, Miki Ohta, Tadashi Goto, Fumihiko Kanai, Naoya Kato, Haruhiko Yoshida, Takao Kawabe, Osamu Yokosuka, Masao Omata, Rapid detection of the hepatitis B virus YMDD mutant using TaqMan-minor groove binder probes, Clinica Chimica Acta, 2008, 395, 1-2, 151

    CrossRef

  22. 22
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  23. 23
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  24. 24
    X. P. Pan, L. J. Li, W. B. Du, M. W. Li, H. C. Cao, J. F. Sheng, Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C, Journal of Viral Hepatitis, 2007, 14, 11
  25. 25
    Masaru Enomoto, Akihiro Tamori, Madoka Toyama Kohmoto, Hiroyasu Morikawa, Daiki Habu, Hiroki Sakaguchi, Tadashi Takeda, Shuichi Seki, Norifumi Kawada, Susumu Shiomi, Shuhei Nishiguchi, Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences, Journal of Medical Virology, 2007, 79, 11
  26. 26
    Chee-Kin Hui, George K. Lau, Treatment of hepatitis B e antigen-negative patients, Current Treatment Options in Gastroenterology, 2007, 10, 6, 474

    CrossRef

  27. 27
    Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hitomi Sezaki, Yasuji Arase, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Kenji Ikeda, Mariko Kobayashi, Marie Matsuda, Junko Satoh, Sachiyo Watahiki, Hiromitsu Kumada, Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants, Journal of Medical Virology, 2006, 78, 3
  28. 28
    Morris Sherman, Cihan Yurdaydin, Jose Sollano, Marcelo Silva, Yun–Fan Liaw, Janusz Cianciara, Anna Boron–Kaczmarska, Paul Martin, Zachary Goodman, Richard Colonno, Anne Cross, Gail Denisky, Bruce Kreter, Robert Hindes, Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B, Gastroenterology, 2006, 130, 7, 2039

    CrossRef

  29. 29
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 2, 425

    CrossRef

  30. 30
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 4, 895

    CrossRef

  31. 31
    Osamu Yokosuka, Makoto Arai, Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B, Medical Molecular Morphology, 2006, 39, 3, 113

    CrossRef

  32. 32
    Y.-F. Liaw, C.-M. Lee, R.-N. Chien, C.-T. Yeh, Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis, Journal of Viral Hepatitis, 2006, 13, 4
  33. 33
    Jian Sun, Zhanhui Wang, Shiwu Ma, Guobing Zeng, Zhiyong Zhou, Kangxian Luo, Jinlin Hou, Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience, Journal of Medical Virology, 2005, 75, 3
  34. 34
    Ke-zhou Liu, Wei Hou, Edward Zumbika, Qin Ni, Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy, Journal of Zhejiang University SCIENCE B, 2005, 6, 12, 1182

    CrossRef

  35. 35
    Man-Fung Yuen, Danny Ka-Ho Wong, Simon Siu-Man Sum, He-Jun Yuan, John Chi-Hang Yuen, Annie On-On Chan, Benjamin Chun-Yu Wong, Ching-Lung Lai, Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection, The American Journal of Gastroenterology, 2005, 100, 5, 1099

    CrossRef

  36. 36
    Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada, Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study, Journal of Medical Virology, 2005, 75, 4
  37. 37
    Ji-Ming Zhang, Xin Yao, Yong-Xiang Wang, Fang Liu, Zhang-Mei Ma, Xing-Hua Weng, Yu-Mei Wen, High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations, Journal of Medical Virology, 2005, 77, 2
  38. 38
    Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 27

    CrossRef

  39. 39
    Marie-Noëlle Brunelle, Anne-Carole Jacquard, Christian Pichoud, David Durantel, Sandra Carrouée-Durantel, Jean-Pierre Villeneuve, Christian Trépo, Fabien Zoulim, Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, 2005, 41, 6
  40. 40
    Samuel Litwin, Eugene Toll, Allison R. Jilbert, William S. Mason, The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations, Journal of Clinical Virology, 2005, 34, S96

    CrossRef

  41. 41
    Yun-Fan Liaw, The current management of HBV drug resistance, Journal of Clinical Virology, 2005, 34, S143

    CrossRef

  42. 42
    Norio Akuta, Fumitaka Suzuki, Mariko Kobayashi, Marie Matsuda, Junko Sato, Yoshiyuki Suzuki, Hitomi Sezaki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment, Intervirology, 2005, 48, 2-3, 174

    CrossRef

  43. 43
    Daryl T.-Y. Lau, Fernando E. Membreno, Antiviral therapy for treatment-naı̈ve hepatitis B virus patients, Gastroenterology Clinics of North America, 2004, 33, 3, 581

    CrossRef

  44. 44
    V. W.-S. Wong, H. L.-Y. Chan, M. L. Wong, J. S.-L. Tam, N. W.-Y. Leung, Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants, Alimentary Pharmacology & Therapeutics, 2004, 19, 3
  45. 45
    Chun-Tao Wai, Robert J Fontana, Clinical significance of hepatitis B virus genotypes, variants, and mutants, Clinics in Liver Disease, 2004, 8, 2, 321

    CrossRef

  46. 46
    Young-Suk Lim, Dong Jin Suh, Current Antiviral Therapy for Chronic Hepatitis B, Journal of Korean Medical Science, 2004, 19, 4, 489

    CrossRef

  47. 47
    TING-TSUNG CHANG, CHING-LUNG LAI, RONG-NAN CHIEN, RICHARD GUAN, SENG-GEE LIM, CHUAN-MO LEE, KENG-YEEN NG, GRAHAM J NICHOLLS, JULIE C DENT, NANCY WY LEUNG, Four years of lamivudine treatment in Chinese patients with chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2004, 19, 11
  48. 48
    Sonia Rodrı́guez-Nóvoa, Antonio Gómez-Tato, Antonio Aguilera-Guirao, Javier Castroagudı́n, Arturo González-Quintela, Carlos Garcia-Riestra, Benito J. Regueiro, Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance, Journal of Virological Methods, 2004, 115, 1, 9

    CrossRef

  49. 49
    Chee-kin Hui, Hai-ying Zhang, George K.K. Lau, Management of chronic hepatitis B in treatment-experienced patients, Gastroenterology Clinics of North America, 2004, 33, 3, 601

    CrossRef

  50. 50
    Henry Lik-Yuen Chan, Albert Ka-Keung Chui, Wan-Yee Lau, Francis Ka-Leung Chan, Alex Yui Hui, Araga Ramesha Nitin Rao, John Wong, Eric Chun-Hung Lai, Joseph Jao-Yiu Sung, Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis, Clinical Transplantation, 2004, 18, 3
  51. 51
    James R Jacob, Brent E Korba, Paul J Cote, Ilia Toshkov, William E Delaney IV, John L Gerin, Bud C Tennant, Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model, Antiviral Research, 2004, 63, 2, 115

    CrossRef

  52. 52
    Man-Fung Yuen, Takanobu Kato, Masashi Mizokami, Annie On-On Chan, John Chi-Hang Yuen, He-Jun Yuan, Danny Ka-Ho Wong, Siu-Man Sum, Irene Oi-Lin Ng, Sheung-Tat Fan, Ching-Lung Lai, Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations, Journal of Hepatology, 2003, 39, 5, 850

    CrossRef

  53. 53
    Kyun-Hwan Kim, Kwang-Hee Lee, Hye-Young Chang, Sang Hoon Ahn, Shuping Tong, Young Joon Yoon, Baik L. Seong, Soon Il Kim, Kwang-Hyub Han, Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy, Journal of Medical Virology, 2003, 71, 3
  54. 54
    Jean-Michel Pawlotsky, Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics, Journal of Hepatology, 2003, 39, 31

    CrossRef

  55. 55
    Scott Bowden, Angeline Bartholomeusz, Stephen Locarnini, Lamivudine resistant occult HBV: implications for public health?, Journal of Hepatology, 2003, 38, 4, 526

    CrossRef

  56. 56
    Anna S.F Lok, Ching-Lung Lai, Nancy Leung, Guang-Bi Yao, Zhen-Yu Cui, Eugene R Schiff, Jules L Dienstag, E.Jenny Heathcote, Nancy R Little, Dorothea A Griffiths, Stephen D Gardner, Mary Castiglia, Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, 2003, 125, 6, 1714

    CrossRef

  57. 57
    Andy S Yu, Emmet B Keeffe, Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period, Clinics in Liver Disease, 2003, 7, 3, 551

    CrossRef

  58. 58
    Daniel Seehofer, Nada Rayes, Peter Neuhaus, Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era, Expert Review of Anti-infective Therapy, 2003, 1, 2, 307

    CrossRef

  59. 59
    Norio Akuta, Fumitaka Suzuki, Mariko Kobayashi, Marie Matsuda, Junko Sato, Kimiko Takagi, Akihito Tsubota, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy, Journal of Medical Virology, 2003, 71, 4
  60. 60
    A. M. Bozdayi̇, Ö. Uzunalimoğlu, A. R. Türkyi̇lmaz, N. Aslan, O. Sezgin, T. Sahin, G. Bozdayi̇, K. Çi̇nar, S. B. Pai, R. Pai, H. Bozkaya, S. Karayalçi̇n, C. Yurdaydi̇n, R. F. Schinazi, YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine, Journal of Viral Hepatitis, 2003, 10, 4
  61. 61
    Robert J. Fontana, Hie-Won L. Hann, Robert P. Perrillo, John M. Vierling, Theresa Wright, Jorge Rakela, Gaya Anschuetz, Randy Davis, Stephen D. Gardner, Nathaniel A. Brown, Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy, Gastroenterology, 2002, 123, 3, 719

    CrossRef

  62. 62
    Chiu-Ching HUANG, Hepatitis infection in haemodialysis patients, Nephrology, 2002, 7, 3
  63. 63
    CHUTIMA PRAMOOLSINSUP, Management of viral hepatitis B, Journal of Gastroenterology and Hepatology, 2002, 17,
  64. 64
    YUN-FAN LIAW, Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2002, 17,
  65. 65
    Jean–Michel Pawlotsky, Molecular diagnosis of viral hepatitis, Gastroenterology, 2002, 122, 6, 1554

    CrossRef

  66. 66
    Fumitaka Suzuki, Yoshiyuki Suzuki, Akihito Tsubota, Norio Akuta, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy, Journal of Hepatology, 2002, 37, 6, 824

    CrossRef

  67. 67
    Masatoshi FUJIWARA, Shyh-Yuh LIOU, Pharmacological and clinical profile of lamivudine(Zefix)., Folia Pharmacologica Japonica, 2002, 120, 1, 55

    CrossRef

  68. 68
    Joseph Torresi, Linda Earnest-Silveira, Gilda Civitico, Tomos E. Walters, Sharon R. Lewin, Janet Fyfe, Stephen A. Locarnini, Michael Manns, Christian Trautwein, Thomas C. Bock, Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the “Fingers” Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene, Virology, 2002, 299, 1, 88

    CrossRef

  69. 69
    Joseph Torresi, The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus, Journal of Clinical Virology, 2002, 25, 2, 97

    CrossRef

  70. 70
    Mark V Galan, Stuart C Gordon, Douglas Boyce, Current pharmacotherapy for hepatitis B infection, Expert Opinion on Pharmacotherapy, 2001, 2, 8, 1289

    CrossRef

  71. 71
    Satsuki Kobayashi, Tatsuya Ide, Michio Sata, Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers, Journal of Hepatology, 2001, 34, 4, 584

    CrossRef

  72. 72
    Béatrice Seignères, Stéphanie Aguesse-Germon, Christian Pichoud, Isabelle Vuillermoz, Catherine Jamard, Christian Trépo, Fabien Zoulim, Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo, Journal of Hepatology, 2001, 34, 1, 114

    CrossRef

  73. 73
    Rienk E Jeeninga, Wilco Keulen, Charles Boucher, Rogier W Sanders, Ben Berkhout, Evolution of AZT Resistance in HIV-1: The 41-70 Intermediate That Is Not Observed in Vivo Has a Replication Defect, Virology, 2001, 283, 2, 294

    CrossRef

  74. 74
    Karl P Fischer, Klaus S Gutfreund, D.Lorne Tyrrell, Lamivudine resistance in hepatitis B: mechanisms and clinical implications, Drug Resistance Updates, 2001, 4, 2, 118

    CrossRef

  75. 75
    Martin R Burda, Stephan Günther, Maura Dandri, Hans Will, Jörg Petersen, Structural and functional heterogeneity of naturally occurring hepatitis B virus variants, Antiviral Research, 2001, 52, 2, 125

    CrossRef

  76. 76
    Suzane Kioko Ono, Naoya Kato, Yasushi Shiratori, Jun Kato, Tadashi Goto, Raymond F. Schinazi, Flair José Carrilho, Masao Omata, The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance, Journal of Clinical Investigation, 2001, 107, 4, 449

    CrossRef

  77. 77
    Tim Shaw, Stephen Locarnini, Combination Chemotherapy for Hepatitis B Virus, Drugs, 2000, 60, 3, 517

    CrossRef

  78. 78
    Deenan Pillay, Patricia A. Cane, Daina Ratcliffe, Mark Atkins, David Cooper, Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study, AIDS, 2000, 14, 9, 1111

    CrossRef

  79. 79
    St Fan, St Cheung, Cm Lo, Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2000, 15,
  80. 80
    Yuki Terui, Takafumi Saito, Hisayoshi Watanabe, Masanori Aoki, Hiroko Haga, Shintaro Miyano, Tadashi Takeda, Koji Saito, Hitoshi Togashi, Haruhide Shinzawa, Tsuneo Takahashi, Lamivudine as an Alternative Therapy for Interferon-Resistant Chronic Hepatitis B and the Characteristics of Hepatitis B Virus: A Case Report, The Tohoku Journal of Experimental Medicine, 2000, 191, 4, 247

    CrossRef

  81. 81
    K. Deres, H. Rübsamen-Waigmann, Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV, Infection, 1999, 27, S2, S45

    CrossRef

  82. 82
    Suzane Kioko Ono-Nita, Naoya Kato, Yasushi Shiratori, Keng-Hsin Lan, Hideo Yoshida, Flair José Carrilho, Masao Omata, Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors, Journal of Clinical Investigation, 1999, 103, 12, 1635

    CrossRef

  83. 83
    Fabien Zoulim, Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies, Antiviral Research, 1999, 44, 1, 1

    CrossRef

  84. 84
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,